{"id":1992,"date":"2025-06-18T18:33:19","date_gmt":"2025-06-18T13:03:19","guid":{"rendered":"https:\/\/mediumturquoise-hedgehog-745891.hostingersite.com\/blogs\/?p=1992"},"modified":"2026-03-10T22:02:14","modified_gmt":"2026-03-10T16:32:14","slug":"guide-to-advanced-biologics","status":"publish","type":"post","link":"https:\/\/www.entrepreneurindia.co\/blogs\/guide-to-advanced-biologics\/","title":{"rendered":"India\u2019s Bioconjugation Goldmine: A Startup Guide to Advanced Biologics"},"content":{"rendered":"\r\n

Biologics and bioconjugation exemplify the growth potential of life sciences. Chemical Weekly\u2019s<\/em> June 3, 2025 issue reported on Shilpa Biologicals\u2019 expanding bioconjugation capabilities in its Dharwad facility, which confirms India\u2019s global value chains focus strategy shift toward Advanced biologics and conjugated pharmaceuticals.<\/p>\r\n\r\n\r\n\r\n

Indian entrepreneurs and biotech<\/a> startups view this as more than mere corporate news: it is an insight into some of the most promising sectors in bioconjugation and biotechnology.<\/p>\r\n\r\n\r\n\r\n

Technological development of therapeutics relies heavily on bioconjugation\u2014the coupling of drug molecules to proteins, peptides, or antibodies, and even to dyes or polymers. It starts from antibody-drug conjugates (ADCs) in oncology to biosensors and diagnostic tools; the field is teeming with opportunities.<\/p>\r\n\r\n\r\n\r\n

The aim of this article is to examine supporting data and trends on emerging business strategies to unlock this bioconjugation opportunity for startups and capitalize on the profit potential of this biotechnology goldmine.<\/p>\r\n\r\n\r\n\r\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n